The introduction of a new extracorporeal therapy in intensive care requires a maximum effort in the medical-scientific area in order to quickly establish evidence of efficacy, but also an extensive knowledge on additional effects, such as interactions with established therapies. Both are the basis for a fast growing acceptance, a future recommendation as standard therapy and for reimbursement of costs in the different healthcare systems. We at CytoSorbents are continuously working on building and expanding this knowledge and clinical evidence on the CytoSorb therapy, and then provide this information to our clinical application partners.
In addition to various multicenter study projects in Europe and the USA, which we perform as a sponsor, we work in a variety of multi- and mono-centric projects closely together with renowned international study partners to make the use of the CytoSorb therapy even more effective and targeted.
Moreover, a large international registry, created at the highest scientific level will systematically provide important insights into safety and effects of the therapy in the clinical routine.
This rapid and efficient medical development of therapy demands the highest level of medical expertise, quality and safety. Errors that occurred in the introduction of other or similar therapies should absolutely be avoided. In order to provide all this, CytoSorbents already now employs 5 physicians in management, who have a wide range of expertise and a major spectrum of clinical experience in the fields of anesthesia/intensive care, thoracic and cardiac surgery, internal medicine, extracorporeal circulation and liver disease.
We are happy to anytime remain at your disposal for your medical and scientific questions.
On the following pages you will find an overview of the most important recent study projects.